[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,505,457
  • Shares Outstanding, K 282,651
  • Annual Sales, $ 812,030 K
  • Annual Income, $ -68,090 K
  • EBIT $ 20 M
  • EBITDA $ 55 M
  • 60-Month Beta N/A
  • Price/Sales 5.62
  • Price/Cash Flow 10.13
  • Price/Book 7.89

Options Overview Details

View History
  • Implied Volatility 83.92% (+8.17%)
  • Historical Volatility 84.83%
  • IV Percentile 54%
  • IV Rank 38.40%
  • IV High 132.24% on 03/18/26
  • IV Low 53.81% on 01/21/26
  • Expected Move (DTE 3) 1.57 (9.61%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 205
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 7,473
  • Open Int (30-Day) 6,578
  • Expected Range 14.80 to 17.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.01
  • Number of Estimates 4
  • High Estimate $0.02
  • Low Estimate $0.00
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) +101.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.70 +6.56%
on 05/11/26
22.16 -24.50%
on 04/21/26
-1.32 (-7.31%)
since 04/10/26
3-Month
15.70 +6.56%
on 05/11/26
22.16 -24.50%
on 04/21/26
-3.92 (-18.98%)
since 02/12/26

Most Recent Stories

More News
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination

CAI : 16.76 (+5.14%)
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

IRVING, Texas , May 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 16.76 (+5.14%)
Caris Life Sciences Q1 Earnings Call Highlights

Caris Life Sciences (NASDAQ:CAI) reported first-quarter 2026 results highlighted by sharp year-over-year revenue growth, improving margins, and continued progress across its pipeline, including a key clinical...

CAI : 16.76 (+5.14%)
Caris Life Sciences Reports First Quarter 2026 Financial Results

Revenue growth of 79% driven by strong performance in molecular profiling services

CAI : 16.76 (+5.14%)
Caris Life Sciences Reports Tomorrow but Reimbursement Reality May Finally Catch Up

Barchart Research What to Expect from CAI Earnings CAI Generated May 6, 2026 Current Price $19.13 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 8.68% Caris Life Sciences Reports Tomorrow...

CAI : 16.76 (+5.14%)
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer

CAI : 16.76 (+5.14%)
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

IRVING, Texas , May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 16.76 (+5.14%)
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers

CAI : 16.76 (+5.14%)
Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

IRVING, Texas , April 24, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 16.76 (+5.14%)
Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

IRVING, Texas , April 20, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 16.76 (+5.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 17.13
2nd Resistance Point 16.79
1st Resistance Point 16.37
Last Price 16.76
1st Support Level 15.61
2nd Support Level 15.27
3rd Support Level 14.85

See More

52-Week High 42.50
Fibonacci 61.8% 32.26
Fibonacci 50% 29.10
Fibonacci 38.2% 25.94
Last Price 16.76
52-Week Low 15.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.